Author

K. S. Anderson

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Biophysics· 1 Cancer Biology· 1 Immunology· 1 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Organism:human· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:chromatin & epigenetic regulation· 1 Approach:deep learning· 1 Assay:DNA methylation· 1 Research Focus:drug response / drug discovery· 1 Organism:mouse· 1

Frequent Co-Authors

A. R. A. Anderson· 1 shared B. A. Desimmie· 1 shared B. Troan· 1 shared C. C. Maley· 1 shared C. Liu· 1 shared C.-H. Zhang· 1 shared D. Northfelt· 1 shared D. Saha· 1 shared

Activity by Year

2017-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 16 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. R. A. Anderson

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Testing Adaptive Therapy Protocols using Gemcitabine and Capecitabine on a Mouse Model of Endocrine-Resistant Breast Cancer

S. SEYEDI, R. Teo, L. Foster, D. Saha, L. Mina, D. Northfelt, K. S. Anderson, D. Shibata, R. Gatenby, L. Cisneros, B. Troan, A. R. A. Anderson, C. C. Maley

This study tests adaptive therapy protocols using gemcitabine and capecitabine on a mouse model of endocrine-resistant breast cancer, finding improved survival with adaptive strategies over high-dose combination therapy.

bioRxiv · Sep 18, 2023 · PreprintCancer Biology

Identification of 14 Known Drugs as Inhibitors of the Main Protease of SARS-CoV-2

M. M. Ghahremanpour, J. Tirado-Rives, M. Deshmukh, J. A. Ippolito, C.-H. Zhang, I. Cabeza de Vaca, M.-E. Liosi, K. S. Anderson, W. L. Jorgensen

The paper identifies 14 known drugs that inhibit SARS-CoV-2 main protease, with five showing IC50 values below 40 μM.

bioRxiv · Aug 28, 2020Pharmacology & Toxicology

Multifunctional CRISPR/Cas9 with engineered immunosilenced human T cell epitopes

S. R. Ferdosi, R. Ewaisha, F. Moghadam, S. Krishna, J. G. Park, M. R. Ebrahimkhani, S. Kiani, K. S. Anderson

This study shows that Cas9 can be modified to reduce immunogenicity while maintaining its function.

bioRxiv · Jul 2, 2018Immunology

Insights into DNA substrate selection by APOBEC3G from structural, biochemical, and functional studies.

S. J. Ziegler, C. Liu, M. Landau, O. Buzovetsky, B. A. Desimmie, Q. Zhao, T. Sasaki, R. C. Burdick, V. K. Pathak, K. S. Anderson, Y. Xiong

This study investigates how APOBEC3G selects DNA substrates through structural, biochemical, and functional analyses, revealing key interactions and mechanisms involved in its antiviral activity against HIV-1.

bioRxiv · Dec 16, 2017Biophysics